Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Exanta Liver Safety Is Key Approval Issue, Company Says

Executive Summary

AstraZeneca's discussions with FDA over the safety profile of its investigational anticoagulant Exanta will center on elevated liver enzyme levels reported during clinical trials
Advertisement

Related Content

Astra Joint Venture Keeps Paying Dividends For Merck; “True Up” Due In 2008
AstraZeneca Crestor, Exanta Promotions Will Focus On Dosing Advantages
AstraZeneca Exanta NDA Filing Set For 2003; Cost-Effective Vs. Warfarin?
AstraZeneca Exanta NDA Filing Set For 2003; Cost-Effective Vs. Warfarin?
Advertisement
UsernamePublicRestriction

Register

PS042223

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel